Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease

NCT07753850 is registered in ClinicalTrials.gov with Shattuck Labs, Inc. as lead sponsor.

NCT NCT07753850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07753850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease
Lead sponsor
Shattuck Labs, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2030
Enrollment
232 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease